Work

Enfortumab vedotin induced cutaneous manifestations

Year: 2025

Type: article

Abstract: Enfortumab vedotin(EV) comprises of an anti–nectin-4 monoclonal antibody bound to the chemotherapeutic agent called monomethyl auristatin E, forming an antibody-drug conjugate. It is currently approved for the treatment of locally advanced or metastatic urothelial carcinoma after disease progression on two prior lines of therapy including chemotherapy and immunotherapy. Since nectin-4 is also expressed on the surface of keratinocytes, cutaneous adverse effects are common. Our clinical image depicts a cutaneous adverse reaction to EV and its resolution after discontinuation of EV.

Source: Advances in Clinical Medical Research and Healthcare Delivery

DOI: 10.53785/2769-2779.1269

Authors: Zeni Kharel, Farhan S Imran

Institutions: Rochester General Hospital, Unity Health System

Language: English

Topic: Chemotherapy-related skin toxicity

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W4407203562

FWCI:

Cites:

Cited by:

Related to: 10